ZA200702392B - New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carbo xylic acid for the treatment of hyper-proliferative disorders - Google Patents

New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carbo xylic acid for the treatment of hyper-proliferative disorders

Info

Publication number: ZA200702392B
Authority: ZA; South Africa
Prior art keywords: ureido; hyper; phenoxy; trifluoromethyl; fluoro
Prior art date: 2004-08-27

Application number

ZA200702392A

Other languages

English (en)

Inventor

Dumas Jacques

Zuleger Suzanne

Ehrlich Paul

Original Assignee

Bayer Pharmaceuticals Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-08-27

Filing date

2007-03-22

Publication date

2008-11-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35517032&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200702392(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-03-22 Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp

2008-11-26 Publication of ZA200702392B publication Critical patent/ZA200702392B/xx

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Biophysics (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Pyridine Compounds (AREA)
Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)

ZA200702392A 2004-08-27 2007-03-22 New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carbo xylic acid for the treatment of hyper-proliferative disorders ZA200702392B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US60475204P	2004-08-27	2004-08-27

Publications (1)

Publication Number	Publication Date
ZA200702392B true ZA200702392B (en)	2008-11-26

Family

ID=35517032

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200702392A ZA200702392B (en)	2004-08-27	2007-03-22	New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carbo xylic acid for the treatment of hyper-proliferative disorders

Country Status (41)

Country	Link
US (2)	US20060058358A1 (zh)
EP (2)	EP1793824B1 (zh)
JP (1)	JP5017115B2 (zh)
KR (1)	KR101336737B1 (zh)
CN (2)	CN101287463A (zh)
AR (1)	AR050616A1 (zh)
AU (1)	AU2005279996A1 (zh)
BR (1)	BRPI0514715B1 (zh)
CA (1)	CA2578438C (zh)
CL (1)	CL2010001484A1 (zh)
CR (1)	CR8980A (zh)
CY (1)	CY2017038I2 (zh)
DK (1)	DK1793824T3 (zh)
EA (1)	EA010832B1 (zh)
EC (1)	ECSP077299A (zh)
ES (1)	ES2561618T3 (zh)
GT (1)	GT200500230A (zh)
HN (1)	HN2005000484A (zh)
HR (1)	HRP20160156T1 (zh)
HU (2)	HUE026654T2 (zh)
IL (1)	IL181590A (zh)
LT (1)	LTC1793824I2 (zh)
LU (1)	LUC00047I2 (zh)
MA (1)	MA28911B1 (zh)
ME (2)	ME00152B (zh)
MX (1)	MX2007002397A (zh)
MY (1)	MY191349A (zh)
NI (1)	NI200700064A (zh)
NO (2)	NO343937B1 (zh)
NZ (1)	NZ553557A (zh)
PE (2)	PE20100432A1 (zh)
PL (1)	PL1793824T3 (zh)
PT (1)	PT1793824E (zh)
RS (1)	RS54580B1 (zh)
SI (1)	SI1793824T1 (zh)
TN (1)	TNSN07076A1 (zh)
TW (1)	TWI369987B (zh)
UA (1)	UA92472C2 (zh)
UY (1)	UY29086A1 (zh)
WO (1)	WO2006026500A1 (zh)
ZA (1)	ZA200702392B (zh)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE556713T1 (de) *	1999-01-13	2012-05-15	Bayer Healthcare Llc	Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) *	2001-04-20	2008-05-13	Bayer Pharmaceuticals Corporation	Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
US20080108672A1 (en) *	2002-01-11	2008-05-08	Bernd Riedl	Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
AU2003209116A1 (en)	2002-02-11	2003-09-04	Bayer Pharmaceuticals Corporation	Aryl ureas with angiogenesis inhibiting activity
US7557129B2 (en) *	2003-02-28	2009-07-07	Bayer Healthcare Llc	Cyanopyridine derivatives useful in the treatment of cancer and other disorders
PT1636585E (pt) *	2003-05-20	2008-03-27	Bayer Pharmaceuticals Corp	Diarilureias com actividade inibidora de cinase
NZ544920A (en) *	2003-07-23	2009-11-27	Bayer Healthcare Llc	4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
KR101239489B1 (ko) *	2004-09-29	2013-03-06	바이엘 파마 악티엔게젤샤프트	열역학적으로 안정한 형태의 ｂａｙ 43-9006 토실레이트
NZ561178A (en) *	2005-03-07	2010-11-26	Bayer Schering Pharma Ag	Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
US8119655B2 (en)	2005-10-07	2012-02-21	Takeda Pharmaceutical Company Limited	Kinase inhibitors
US20090074917A2 (en) *	2006-07-26	2009-03-19	Remington Direct Lp	Low-calorie, no laxation bulking system
US20080026038A1 (en) *	2006-07-26	2008-01-31	Remington Direct Lp	No laxation, low flatulence bulking system
JP2010505962A (ja)	2006-10-09	2010-02-25	武田薬品工業株式会社	キナーゼ阻害剤
AR062927A1 (es) *	2006-10-11	2008-12-17	Bayer Healthcare Ag	4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
EP1920767A1 (en) *	2006-11-09	2008-05-14	Abbott GmbH & Co. KG	Melt-processed imatinib dosage form
US20100143459A1 (en) *	2006-11-09	2010-06-10	Abbott Gmbh & Co. Kg	Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
TWI494133B (zh)	2007-03-14	2015-08-01	Tibotec Pharm Ltd	重組用粉末
WO2008138755A2 (en) *	2007-05-11	2008-11-20	F. Hoffmann-La Roche Ag	Pharmaceutical compositions for poorly soluble drugs
WO2009114703A2 (en) *	2008-03-12	2009-09-17	Fox Chase Cancer Center	Combination therapy for the treatment of cancer
UA107186C2 (xx) *	2008-12-03	2014-12-10		Тверді форми дозування бендамустину
WO2010068951A1 (en) *	2008-12-12	2010-06-17	Fox Chase Cancer Center	Combination therapy based on src and aurora kinase inhibition for the treatment of cancer
JO3112B1 (ar) *	2010-03-29	2017-09-20	Ferring Bv	تركيبة دوائية سريعة التحلل
AR081060A1 (es) *	2010-04-15	2012-06-06	Bayer Schering Pharma Ag	Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
CN103002880B (zh) *	2010-06-09	2015-01-28	Abbvie公司	含有激酶抑制剂的固态分散体
EP3750526A1 (en)	2010-07-12	2020-12-16	Salix Pharmaceuticals, Inc.	Formulations of rifaximin and uses thereof
JP2013531067A (ja)	2010-07-19	2013-08-01	バイエルヘルスケアリミティドライアビリティカンパニー	疾病及び状態の処置及び予防のためのフルオロ置換オメガ−カルボキシアリールジフェニル尿素を用いた組み合わせ薬
AP2013006834A0 (en)	2010-10-01	2013-04-30	Bayer Ip Gmbh	Substituted N-(2-arylamino)aryl sulfonamide-containing combinations
UA113500C2 (xx) *	2010-10-29	2017-02-10		Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
ES2699205T3 (es)	2010-10-29	2019-02-07	Abbvie Inc	Dispersiones sólidas que contienen un agente que induce la apoptosis
CN103301066B (zh) *	2012-03-15	2018-12-07	苏州泽璟生物制药有限公司	一种改善吸收性能的固体分散体及其制备
AR092439A1 (es) *	2012-09-06	2015-04-22	Bayer Healthcare Llc	Composicion farmaceutica recubierta que contiene regorafenib
US9211290B2 (en) *	2012-12-31	2015-12-15	Noven Therapeutics, Llc	Solid dispersions of amorphous paroxetine mesylate
US9518020B2 (en)	2013-10-04	2016-12-13	Hetero Research Foundation	Process for Regorafenib
CN104721142B (zh) *	2013-12-18	2020-04-28	山东新时代药业有限公司	一种利伐沙班固体分散体及其制备方法
US9790185B2 (en)	2014-07-09	2017-10-17	Shilpa Medicare Limited	Process for the preparation of regorafenib and its crystalline forms
CN105267167A (zh) *	2015-09-11	2016-01-27	江苏嘉逸医药有限公司	一种瑞戈非尼口服固体药物组合物的制备方法
CN105330600B (zh) *	2015-11-30	2018-05-22	山东罗欣药业集团股份有限公司	一种瑞戈菲尼的制备方法
CN105879049B (zh) *	2016-05-13	2019-03-26	浙江大学	一种瑞戈非尼与β-环糊精的包合物及其制备方法
CN107661296A (zh) *	2016-07-27	2018-02-06	江苏先声药业有限公司	一种瑞戈非尼固体分散体及其制备方法
EP4137132A1 (en)	2016-09-30	2023-02-22	Salix Pharmaceuticals, Inc.	Solid dispersion forms of rifaximin
CN111166724A (zh) *	2018-11-09	2020-05-19	北京化工大学	一种瑞戈非尼纳米分散体、片剂及其制备方法
EP3861989A1 (en) *	2020-02-07	2021-08-11	Bayer Aktiengesellschaft	Pharmaceutical composition containing regorafenib and a stabilizing agent
BR112022017758A2 (pt) *	2020-03-05	2022-11-29	Aurigene Discovery Tech Ltd	Composições farmacêuticas de um inibidor de quinase
CN112587485A (zh) *	2021-01-08	2021-04-02	湖南南新制药股份有限公司	一种药物固体分散体及其制备方法
CN112842998A (zh) *	2021-01-19	2021-05-28	深圳市简一生物科技有限公司	一种瑞戈非尼分散剂及其制备方法
FR3123358B1 (fr) *	2021-05-25	2024-05-10	Vecormat Bfc	Procédé d’élaboration d’un matériau naturel composite à faible emprunte carbone et fort taux de matière naturelle.
WO2022253945A1 (en)	2021-06-04	2022-12-08	Bayer Aktiengesellschaft	Pharmaceutical dosage forms comprising 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}-benzamide
CN114767633B (zh) *	2022-04-07	2023-03-31	郑州大学第一附属医院	含抗乳腺癌药物他莫昔芬的固体分散体、制备方法及制剂
WO2025242583A1 (en)	2024-05-24	2025-11-27	Bayer Consumer Care Ag	Novel formulation comprising elinzanetant in a solid dispersion

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4151273A (en) *	1974-10-31	1979-04-24	The Regents Of The University Of California	Increasing the absorption rate of insoluble drugs
US4220302A (en)	1978-07-21	1980-09-02	Hampton Diane M	Nursing bottle holder
EP0580860B2 (en) *	1991-04-16	2004-12-15	Nippon Shinyaku Company, Limited	Method of manufacturing solid dispersion
PL205321B1 (pl) *	1997-12-22	2010-04-30	Bayer Corp	Zastosowanie podstawionych heterocyklicznych moczników do wytwarzania leku do hamowania kinazy raf, podstawione heterocykliczne moczniki oraz kompozycja farmaceutyczna je zawierająca
CA2315646C (en) *	1997-12-22	2010-02-09	Bayer Corporation	Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas
TR200002617T2 (tr) *	1997-12-22	2000-11-21	Bayer Corporation	Aril ve heteroaril sübstitüentli heterosiklik üreler kullanılarak RAF kinazın inhibe edilmesi
US7928239B2 (en)	1999-01-13	2011-04-19	Bayer Healthcare Llc	Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
HU230863B1 (hu) *	1999-01-13	2018-10-29	Bayer Healthcare Llc	Omega-karboxi-arilcsoporttal helyettesített difenil-karbamidok, mint raf-kináz inhibitorok
ATE556713T1 (de) *	1999-01-13	2012-05-15	Bayer Healthcare Llc	Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer
EP1140840B1 (en)	1999-01-13	2006-03-22	Bayer Pharmaceuticals Corp.	-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP3789066B2 (ja)	1999-12-08	2006-06-21	三菱電機株式会社	液晶表示装置
CA2407063A1 (en) *	2000-04-19	2001-10-25	Takeo Hirose	Solid dispersion with improved absorbability
US8725620B2 (en)	2000-07-10	2014-05-13	Nobuyoshi Morimoto	System and method for negotiating improved terms for products and services being purchased through the internet
CA2418490A1 (en) *	2000-08-11	2002-02-21	Eisai Co., Ltd.	Drug-containing solid dispersion having improved solubility
PL362979A1 (en)	2000-12-11	2004-11-02	Takeda Chemical Industries, Ltd.	Medicinal compositions improved in solublity in water
US7235576B1 (en) *	2001-01-12	2007-06-26	Bayer Pharmaceuticals Corporation	Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CN1491105A (zh) *	2001-02-13	2004-04-21		新的改进释放的制剂
SE0103838D0 (sv) *	2001-11-16	2001-11-16	Astrazeneca Ab	Pharmaceutical formulation & product
US7307071B2 (en) *	2001-12-04	2007-12-11	Onyx Pharmaceuticals, Inc	RAF-MEK-ERK pathway inhibitors to treat cancer
US20030207872A1 (en) *	2002-01-11	2003-11-06	Bayer Corporation	Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP2005517690A (ja) *	2002-02-01	2005-06-16	ファイザー・プロダクツ・インク	固体薬物分散物を含有する即時放出剤形
AU2003209116A1 (en) *	2002-02-11	2003-09-04	Bayer Pharmaceuticals Corporation	Aryl ureas with angiogenesis inhibiting activity
CA2430180C (en)	2003-05-21	2010-03-16	Royal Group Technologies Limited	Cascade shade
NZ544920A (en) *	2003-07-23	2009-11-27	Bayer Healthcare Llc	4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions
EP1796642B1 (en) *	2004-08-27	2008-05-21	Bayer Pharmaceuticals Corporation	Pharmaceutical compositions in the form of solid dispersions for the treatment of cancer

2005
- 2005-08-25 MY MYPI20054000A patent/MY191349A/en unknown
- 2005-08-26 PE PE2010000029A patent/PE20100432A1/es active IP Right Grant
- 2005-08-26 US US11/212,109 patent/US20060058358A1/en not_active Abandoned
- 2005-08-26 TW TW094129395A patent/TWI369987B/zh not_active IP Right Cessation
- 2005-08-26 GT GT200500230A patent/GT200500230A/es unknown
- 2005-08-26 AR ARP050103568A patent/AR050616A1/es not_active Application Discontinuation
- 2005-08-26 PE PE2005000984A patent/PE20060505A1/es active IP Right Grant
- 2005-08-26 UY UY29086A patent/UY29086A1/es not_active Application Discontinuation
- 2005-08-26 HN HN2005000484A patent/HN2005000484A/es unknown
- 2005-08-29 CN CNA2005800371513A patent/CN101287463A/zh active Pending
- 2005-08-29 PT PT57924862T patent/PT1793824E/pt unknown
- 2005-08-29 EP EP05792486.2A patent/EP1793824B1/en not_active Revoked
- 2005-08-29 EP EP13151040.6A patent/EP2589384A1/en not_active Withdrawn
- 2005-08-29 EA EA200700501A patent/EA010832B1/ru unknown
- 2005-08-29 MX MX2007002397A patent/MX2007002397A/es active IP Right Grant
- 2005-08-29 KR KR1020077006801A patent/KR101336737B1/ko not_active Expired - Lifetime
- 2005-08-29 HU HUE05792486A patent/HUE026654T2/en unknown
- 2005-08-29 AU AU2005279996A patent/AU2005279996A1/en not_active Abandoned
- 2005-08-29 SI SI200532037T patent/SI1793824T1/sl unknown
- 2005-08-29 ME MEP-2008-358A patent/ME00152B/me unknown
- 2005-08-29 WO PCT/US2005/030541 patent/WO2006026500A1/en not_active Ceased
- 2005-08-29 ME MEP-358/08A patent/MEP35808A/xx unknown
- 2005-08-29 BR BRPI0514715-8A patent/BRPI0514715B1/pt active IP Right Grant
- 2005-08-29 ES ES05792486.2T patent/ES2561618T3/es not_active Expired - Lifetime
- 2005-08-29 RS RS20160039A patent/RS54580B1/sr unknown
- 2005-08-29 PL PL05792486T patent/PL1793824T3/pl unknown
- 2005-08-29 HR HRP20160156TT patent/HRP20160156T1/hr unknown
- 2005-08-29 JP JP2007533489A patent/JP5017115B2/ja not_active Expired - Lifetime
- 2005-08-29 NZ NZ553557A patent/NZ553557A/en not_active IP Right Cessation
- 2005-08-29 CA CA2578438A patent/CA2578438C/en not_active Expired - Lifetime
- 2005-08-29 DK DK05792486.2T patent/DK1793824T3/en active
- 2005-08-29 CN CN2012102807209A patent/CN102885813A/zh active Pending
- 2005-08-29 UA UAA200703203A patent/UA92472C2/ru unknown
2007
- 2007-02-26 TN TNP2007000076A patent/TNSN07076A1/en unknown
- 2007-02-27 NI NI200700064A patent/NI200700064A/es unknown
- 2007-02-27 IL IL181590A patent/IL181590A/en active IP Right Grant
- 2007-03-05 EC EC2007007299A patent/ECSP077299A/es unknown
- 2007-03-07 CR CR8980A patent/CR8980A/es unknown
- 2007-03-22 ZA ZA200702392A patent/ZA200702392B/xx unknown
- 2007-03-22 MA MA29767A patent/MA28911B1/fr unknown
- 2007-03-26 NO NO20071584A patent/NO343937B1/no active Protection Beyond IP Right Term
2010
- 2010-12-20 CL CL2010001484A patent/CL2010001484A1/es unknown
2016
- 2016-03-22 LT LTPA2016008C patent/LTC1793824I2/lt unknown
2017
- 2017-01-27 US US15/417,469 patent/US20170165243A1/en not_active Abandoned
- 2017-11-08 LU LU00047C patent/LUC00047I2/fr unknown
- 2017-11-09 CY CY2017038C patent/CY2017038I2/el unknown
- 2017-11-21 HU HUS1700047C patent/HUS1700047I1/hu unknown
2019
- 2019-08-05 NO NO2019033C patent/NO2019033I1/no unknown

Also Published As

Publication number	Publication date
MA28911B1 (fr)	2007-10-01
HUE026654T2 (en)	2016-07-28
WO2006026500A1 (en)	2006-03-09
HRP20160156T1 (hr)	2016-03-11
LTC1793824I2 (lt)	2017-06-12
PE20060505A1 (es)	2006-06-18
ECSP077299A (es)	2007-04-26
JP5017115B2 (ja)	2012-09-05
MEP35808A (en)	2010-06-10
CY2017038I1 (el)	2018-06-27
LUC00047I2 (zh)	2018-01-10
RS54580B1 (sr)	2016-06-30
NO343937B1 (no)	2019-07-15
IL181590A (en)	2013-04-30
CR8980A (es)	2007-10-22
DK1793824T3 (en)	2016-02-01
IL181590A0 (en)	2007-07-04
EA010832B1 (ru)	2008-12-30
NZ553557A (en)	2010-08-27
UY29086A1 (es)	2006-03-31
PL1793824T3 (pl)	2016-06-30
TW200616627A (en)	2006-06-01
PE20100432A1 (es)	2010-07-21
TNSN07076A1 (en)	2008-06-02
CA2578438C (en)	2015-10-06
HUS1700047I1 (hu)	2017-12-28
EP2589384A1 (en)	2013-05-08
EP1793824B1 (en)	2015-11-18
US20060058358A1 (en)	2006-03-16
US20170165243A1 (en)	2017-06-15
KR101336737B1 (ko)	2013-12-04
UA92472C2 (ru)	2010-11-10
AR050616A1 (es)	2006-11-08
EP1793824A1 (en)	2007-06-13
NI200700064A (es)	2008-03-03
CL2010001484A1 (es)	2011-04-25
SI1793824T1 (sl)	2016-03-31
ES2561618T3 (es)	2016-02-29
GT200500230A (es)	2006-03-28
EA200700501A1 (ru)	2007-08-31
CN102885813A (zh)	2013-01-23
LUC00047I1 (zh)	2017-11-15
NO2019033I1 (no)	2019-08-05
KR20070067104A (ko)	2007-06-27
JP2008511685A (ja)	2008-04-17
HN2005000484A (es)	2010-06-08
TWI369987B (en)	2012-08-11
NO20071584L (no)	2007-05-24
MY191349A (en)	2022-06-17
AU2005279996A1 (en)	2006-03-09
BRPI0514715B1 (pt)	2021-11-03
BRPI0514715A (pt)	2008-06-24
ME00152B (me)	2010-10-10
CY2017038I2 (el)	2018-06-27
MX2007002397A (es)	2007-05-15
PT1793824E (pt)	2016-03-11
CA2578438A1 (en)	2006-03-09
CN101287463A (zh)	2008-10-15

Publication	Publication Date	Title
ZA200702392B (en)	2008-11-26	New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carbo xylic acid for the treatment of hyper-proliferative disorders
EP1833467A4 (en)	2012-09-26	PHARMACEUTICAL COMPOSITIONS FOR SLEEP DISORDERS
IL205624A (en)	2016-10-31	Carboxamide, Sulfonamide and Amine Compounds, Their Pharmaceutical Preparations
IL185277A0 (en)	2008-02-09	Pharmaceutical compositions containing roflumilast for the treatment of diabetes
IL181049A0 (en)	2007-07-04	Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
IL190338A0 (en)	2009-09-22	Biphenyloxyacetic acid derivatives for the treatment of respiratory disease
IL179674A0 (en)	2007-05-15	Chemical compounds and pharmaceutical compositions containing them for the treatment of inflammatory disorders
IL189578A (en)	2015-10-29	Pyridine derivatives, pharmaceutical compounds containing them, and their use in the preparation of drugs for the treatment of cns diseases
IL180680A0 (en)	2007-06-03	Piperazine derivatives useful for the treatment of gastrointestinal disorders
AP2005003424A0 (en)	2005-12-31	Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders; process for their preparation and pharmaceutical compositions containing them.
CY2013021I2 (el)	2025-07-04	Συνθεσεις για τη θεραπευτικη αγωγη γαστροεντερικων διαταραχων
IL190137A (en)	2015-06-30	Lacquinimod crystalline mixtures, pharmaceutical compositions containing them and ways to prepare them
IL182763A (en)	2010-12-30	Indol-3-ylidene-hydrazino-biphenyl- carboxylic acid derivatives and pharmaceutical compositions comprising them for modulating thrombopoietin activity
GB0520751D0 (en)	2005-11-23	Pharmaceutical compositions for the treatment of chronic obstructive pulmonary disease
PL1817282T3 (pl)	2011-11-30	Pochodne kwasu fenoksyoctowego użyteczne do leczenia chorób układu oddechowego
PL377504A1 (pl)	2006-02-06	Pochodne (2-aminofenylo)amidu kwasu arylenokarboksylowego jako środki framaceutyczne
IL191967A0 (en)	2008-12-29	3-(4-{[4-(4-{[3-(3,3-dimethyl-1-piperidinyl) propyl]oxy}phenyl)-1-piperidinyl]carbonyl]-1-naphthalenyl)propanoic or propenoic acid as h1 and h3 receptor antagonists for the treatment of inflammatory and/or allergic disorders
IL170314A (en)	2010-11-30	4 - (3 -(2 - phenyl - oxazol - 4 - ylmethoxy) - cyclohexyloxy) - butane acid derivatives and related compounds, pharmaceutical compositions comprising them and use thereof
EP1899326A4 (en)	2009-12-16	NOVEL AZETIDINE DERIVATIVES USEFUL AS ANTAGONISTS OF NEUROKININ RECEPTORS IN THE TREATMENT OF GASTROINTESTINAL DISEASES
ZA200602840B (en)	2007-09-26	Pharmaceutical compositions comprising malonamide derivatives for decreasing sebum production
AU2003210812A8 (en)	2003-09-02	Stable pharmaceutical composition useful for treating gastrointestinal disorders
MX2007010400A (es)	2008-01-11	Nuevas sales de derivados de hexahidrofenantridina sustituida con 6-heterociclilo.
EP1899318A4 (en)	2010-03-17	NEW AZETIDINE DERIVATIVES AS NEUROKININ RECEPTOR ANTAGONISTS FOR THE TREATMENT OF STOMACH DARM DISEASES
AU2003294100A1 (en)	2004-06-23	Use of hyaluronic acid for respiratory disorders or the upper airways
TWI340643B (en)	2011-04-21	1-[2h-1-benzopyran-2-one-8-yl]-piperazine derivatives for the treatment of movement disorders